Abstract
BackgroundColitis is a well-known subtype of inflammatory bowel disease and is caused by diverse factors. Previous research has shown that KIOM-MA elicits anti-inflammatory and anti-allergic effects on various diseases. KIOM-MA-128, our novel herbal formula, was generated from KIOM-MA using probiotics to improve the therapeutic efficacy. We investigated whether KIOM-MA-128 has protective activity in a mouse model of acute colitis induced by dextran sodium sulfate (DSS).MethodsColitis was induced by DSS administered to ICR mice in drinking water. KIOM-MA-128 (125 or 250 mg/kg) was orally administered once per day. The body weights of the mice were measured daily, and colonic endoscopies were performed at 5 and 8 days. Colon length as well as histological and cytokine changes were observed at the end of drug administration.ResultsKIOM-MA-128 has pharmacological activity in an acute colitis model. KIOM-MA-128 reduced the loss of body weight and disease activity index (DAI) and inhibited the abnormally short colon lengths and the colonic damage in this mouse model of acute colitis. Moreover, KIOM-MA-128 suppressed pro-inflammatory cytokine expression and maintained the integrity of the tight junctions during DSS-induced colitis.ConclusionThe results indicated that KIOM-MA-128 protects against DSS-induced colitis in mice and suggested that this formula might be a candidate treatment for inflammatory bowel disease (IBD).
Highlights
Colitis is a well-known subtype of inflammatory bowel disease and is caused by diverse factors
We investigated the effects of K-M-128 in a dextran sodium sulfate (DSS)-induced mouse colitis model and evaluated whether they underlie the protective effects of this formula against colitis, inflammation, and damage to tight junctions in colonic crypts
DSS-induced colonic disorder was reduced after treatment with KIOM-MA-128
Summary
Colitis is a well-known subtype of inflammatory bowel disease and is caused by diverse factors. Therapeutic approaches to treating colitis include administration of anti-inflammatory drugs and immunomodulators, surgery, and therapies focused on controlling the immune cell-response cytokine pathway; treatments are limited because of several severe side effects such as allergies and lymphoma [4]. For this reason, new therapeutic options are urgently needed to provide more effective and safe treatment, and several. KIOM-MA is composed of Glycyrrhizae Radix (the roots and rhizomes of Glycyrrhiza uralensis), Polygoni Cuspidati Rhizoma Meyer), Scrophulariae Radix (the root of Scrophularia ningpoensis Hemsl.), Zizyphi Semen (the seeds of Zizyphus spinosa Hu), Angelica Gigantis Radix
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
